MGI adn Swiss rockets Partner to Expand Access to Revolutionary coolmps Sequencing Technology
San Diego, CA & Zurich, Switzerland – [Date of Original Release] - In a strategic move poised to reshape the landscape of genomic research and personalized medicine, MGI tech Co., Ltd. and Swiss Rockets AG have announced an exclusive licensing agreement for MGI’s groundbreaking coolmps (cool Multiple Primer Extension) sequencing technology. This collaboration promises to deliver more accurate genomic reads at reduced costs, accelerating advancements in disease prevention, diagnosis, and treatment globally.
A New Era in Sequencing: The Power of CoolMPS
CoolMPS represents a meaningful leap forward in DNA sequencing. Unlike traditional methods, CoolMPS utilizes a novel enzymatic reaction and optimized chemistry to achieve superior accuracy and efficiency. This translates to more reliable genomic data,crucial for applications ranging from cancer research and infectious disease monitoring to personalized drug advancement and preventative healthcare. The technology’s ability to deliver high-quality data at a lower cost point democratizes access to genomic insights, empowering a wider range of researchers and clinicians.
Expanding Global Reach: Swiss Rockets Takes the Helm in Key Markets
Under the terms of the agreement, Swiss Rockets is granted exclusive rights to MGI’s CoolMPS-related intellectual property – encompassing patents, proprietary know-how, and software – for research, development, manufacturing, and commercialization in all markets excluding Asia-Pacific and Greater China. This strategic focus allows both companies to leverage their strengths and maximize the technology’s impact.
Swiss Rockets, bolstered by a recent investment from leading US public health company Emergent BioSolutions, will spearhead the expansion of CoolMPS’s global footprint. The company will focus on manufacturing CoolMPS sequencers and associated consumables for key markets including the United States and Europe.Crucially, Swiss Rockets will integrate CoolMPS into its existing portfolio of innovative solutions, augmenting its capabilities in personalized disease prevention, aging research, and the development of optimal, precision-based treatments.
Industry Leaders Weigh In
“This partnership marks a pivotal step for MGI to maximize the impact of CoolMPS worldwide,” stated Dr. Rade Drmanac, Chief Scientific Officer of MGI. “By joining forces wiht Swiss Rockets, a like-minded innovator, we are accelerating the commercialization and scaling of this groundbreaking sequencing technology, ultimately improving global health. This agreement also reinforces MGI’s financial strength, business focus, and technological leadership, reaffirming our commitment to providing the life science community with choice and innovation.”
Dr. Vladimir Cmiljanovic,CEO of swiss Rockets,echoed this sentiment,adding,”We are excited to license CoolMPS from MGI,enabling Swiss rockets to advance our mission in oncology and viral disease innovation through world-class technology.CoolMPS is a natural complement to our existing drug development pipelines and diagnostic platforms, strengthening our ability to deliver precise, personalized solutions to patients and communities in need.”
MGI: Pioneering Innovation in Life Sciences
MGI Tech Co., Ltd.is a rapidly growing force in the life science industry, dedicated to developing and delivering core tools and technologies that drive innovation. Founded in 2016, MGI has quickly established itself as a leader in the research, development, manufacturing, and sales of instruments, reagents, and related products for a diverse range of applications, including precision medicine, agriculture, healthcare, and beyond.
What sets MGI apart is its unique ability to independently develop and mass-produce clinical-grade gene sequencers with varying throughput capacities - from gigabases (Gb) to terabases (Tb). This complete capability, coupled with unparalleled expertise and a commitment to global impact, positions MGI at the forefront of shaping the future of life sciences.
Learn More About MGI:
* https://www.linkedin.com/company/mgi-tech688114
* https://twitter.com/MGI_Technology
* https://www.youtube.com/@MGIInternational
Swiss Rockets AG: Fueling the Next Generation of Biotech Innovation
Swiss Rockets AG operates as both an incubator and accelerator, dedicated to fostering the growth of biotech and precision healthcare start-ups, with a particular focus on oncology. The company’s diverse portfolio of radioligand therapies, small molecules, and vaccines –
